After the 14‐day period of decitabine pretreatment, the leukemic cells were subjected to synergy testing, using 5 nM decitabine in combination with prednisone, asparaginase, cytarabine, daunorubicin, or vincristine, which are currently used in the treatment of MLL‐rearranged infant ALL. This evidence concerns the gene ASPG and acute lymphoblastic leukemia.